Welcome to the trials list!

Some tips to help get started:

  • Click on any trial title to view details, including trial sites, eligibility criteria, and our research about study drugs
  • If the list is long, use the search box and filters on the left to narrow down trials
  • Bookmark trials of interest by clicking the bookmark icon to the right of the trial title
Sign up to save your data! Arrow
Processing... Processing...

Clinical Trials for Non-Small Cell Lung Cancer

Search

Close
[Clear]

Filters

Location:
[Clear]
[Clear]

There are 386 active trials for advanced/metastatic non-small cell lung cancer. Click on a trial to see more information.

386 trials meet filter criteria.

Sort by:

Active drug More information High burden on patient More information
Sponsor: Pfizer (industry) Phase: 1 Start date: July 5, 2022

HealthScout AI summary: The trial involves participants aged 16 and older with advanced solid tumors and BRAF alterations, evaluating the safety and efficacy of PF-07799933, a brain-penetrant pan-mutant BRAF inhibitor, as a monotherapy and in combination with binimetinib and cetuximab.

ClinicalTrials.gov ID: NCT05355701

Investigational drug late phase More information Moderate burden on patient More information No known activity More information
Sponsor: Regeneron Pharmaceuticals (industry) Phase: 2 Start date: April 21, 2023

HealthScout AI summary: The trial enrolls patients with advanced stage IIIB/IIIC or IV NSCLC with high PD-L1 expression (≥50%) to compare the efficacy and safety of cemiplimab monotherapy versus its combination with BNT116, an investigational mRNA cancer vaccine targeting tumor-associated antigens.

ClinicalTrials.gov ID: NCT05557591

Active drug More information High burden on patient More information
Sponsor: Avistone Biotechnology Co., Ltd. (industry) Phase: 1 Start date: July 1, 2024

HealthScout AI summary: This trial enrolls adult patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion, uncommon, classical (Ex19del and L858R), and T790M drug-resistant mutations to evaluate the safety and efficacy of PLB1004, an irreversible EGFR tyrosine kinase inhibitor targeting these mutations while sparing wild-type EGFR.

ClinicalTrials.gov ID: NCT06046495

Active drug More information High burden on patient More information
Sponsor: Servier Bio-Innovation LLC (industry) Phase: 1/2 Start date: Aug. 7, 2024

HealthScout AI summary: This trial involves adult patients with untreated, advanced non-small cell lung cancer and high PD-L1 expression, evaluating cemiplimab combined with novel antibodies targeting TIM3, CD73, or NKG2A to assess safety, efficacy, and treatment outcomes.

ClinicalTrials.gov ID: NCT06162572

Active drug More information Moderate burden on patient More information Started >3 years ago More information
Sponsor: Medicenna Therapeutics, Inc. (industry) Phase: 1/2 Start date: Aug. 27, 2021

HealthScout AI summary: This trial evaluates MDNA11, an IL-2 Superkine targeting the IL-2 beta receptor to enhance anti-tumor immunity, administered alone or with pembrolizumab, in adult patients with locally advanced or metastatic solid tumors. Eligible patients must have an ECOG performance status of 0 or 1 and adequate organ function.

ClinicalTrials.gov ID: NCT05086692

Active drug More information High burden on patient More information
Sponsor: Johnson & Johnson Enterprise Innovation Inc. (industry) Phase: 1 Start date: Nov. 27, 2023

HealthScout AI summary: This study targets patients with stage IIIB-IV NSCLC who have progressed on previous anti-PD-1/PD-L1 therapy and platinum-based chemotherapy, testing JNJ-86974680, an A2a receptor antagonist, both alone and in combination with cetrelimab, a PD-1 inhibitor, and radiation therapy.

ClinicalTrials.gov ID: NCT06116786

Active drug More information High burden on patient More information
Sponsor: Janux Therapeutics (industry) Phase: 1 Start date: April 19, 2023

HealthScout AI summary: The trial targets adult patients with advanced or metastatic EGFR-expressing carcinomas such as NSCLC, CRC, and TNBC, who have exhausted other treatment options, using the investigational bispecific antibody JANX008 designed to activate in the tumor environment by targeting EGFR and CD3.

ClinicalTrials.gov ID: NCT05783622

Active drug More information High burden on patient More information
Sponsor: Janssen Research & Development, LLC (industry) Phase: 1/2 Start date: May 18, 2023

HealthScout AI summary: This trial evaluates the safety and efficacy of the combination of amivantamab and cetrelimab, a PD-1 inhibitor, in metastatic NSCLC patients who have progressed after standard treatment, with patients grouped by EGFR mutation status or PD-L1 expression.

ClinicalTrials.gov ID: NCT05908734

Active drug More information High burden on patient More information
Sponsor: AbbVie (industry) Phase: 1 Start date: Feb. 6, 2024

HealthScout AI summary: This trial includes adult patients with relapsed or refractory advanced solid tumors, such as non-small cell lung cancer, renal cell carcinoma, and head and neck squamous cell carcinoma, who have an ECOG performance status of 0 or 1. It evaluates the safety and efficacy of ABBV-303, a trispecific killer cell engager targeting c-Met, as monotherapy and in combination with budigalimab, a PD-1 inhibitor.

ClinicalTrials.gov ID: NCT06158958

Investigational drug late phase More information Moderate burden on patient More information No known activity More information
Sponsor: Amgen (industry) Phase: 3 Start date: Sept. 9, 2024

HealthScout AI summary: This trial involves patients aged 18 or older with stage IV non-squamous NSCLC, comparing the investigational PD-1 targeting antibody ABP 234 to pembrolizumab, both combined with pemetrexed and either cisplatin or carboplatin chemotherapy. Participants must have measurable disease without prior advanced systemic treatment and meet specific biomarker and genetic criteria.

ClinicalTrials.gov ID: NCT06311721

First Previous Page 8 of 39 Next Last
Please help us improve by giving us feedback or feature requests. Email info@healthscout.app
Copy email address
Email copied to clipboard